Search

Your search keyword '"Tewari, K.S."' showing total 116 results
Start Over Author "Tewari, K.S."
116 results on '"Tewari, K.S."'

2. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe

Author

Levenback, C.F., Hermans, R.H., Bouda, J., Sharma, A., Luesley, D., Ellis, P., Cruickshank, D.J., Duncan, T.J., Kieser, K., Palle, C., Spirtos, N.M., O'Malley, D.M., Leitao, M.M., Geller, M., Dhar, K., Asher, V., Tobias, D.H., Borgfeldt, C., Lea, J.S., Lood, M., Bailey, J., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K.S., Persson, P., Manchanda, R., Jensen, P., Van Le, L., Van der Kolk, W.L., Van der Zee, A.G.J., Slomovitz, B.M., Baldwin, P.J.W., Van Doorn, H.C., De Hullu, J.A., Van der Velden, J., Gaarenstroom, K.N., Slangen, B.F.M., Kjolhede, P., Brännström, M., Vergote, I., Holland, C.M., Coleman, R., Van Dorst, E.B.L., Van Driel, W.J., Nunns, D., Widschwendter, M., Nugent, D., DiSilvestro, P.A., Mannel, R.S., Tjiong, M.Y., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Monk, B.J., Zanagnolo, V., Tamussino, K., and Oonk, M.H.M.

Published
2022
Full Text
View/download PDF

5. 168P Liver metastases (mets) and treatment effect of cemiplimab-based therapy: An analysis from three phase III trials (EMPOWER-Lung 1, EMPOWER-Lung 3 part 2, and EMPOWER-Cervical 1)

Author

Baramidze, A., primary, Gessner, C., additional, Gogishvili, M., additional, Sezer, A., additional, Makharadze, T., additional, Kilickap, S., additional, Gumus, M., additional, Tewari, K.S., additional, Monk, B.J., additional, de Melo, A.C., additional, Oaknin, A., additional, Li, S., additional, Gao, B., additional, Mathias, M.D., additional, Gullo, G., additional, Salvati, M.E., additional, Seebach, F., additional, Lowy, I., additional, Fury, M., additional, and Rietschel, P., additional

Published
2022
Full Text
View/download PDF

7. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe

Author

Van der Kolk, W.L., primary, Van der Zee, A.G.J., additional, Slomovitz, B.M., additional, Baldwin, P.J.W., additional, Van Doorn, H.C., additional, De Hullu, J.A., additional, Van der Velden, J., additional, Gaarenstroom, K.N., additional, Slangen, B.F.M., additional, Kjolhede, P., additional, Brännström, M., additional, Vergote, I., additional, Holland, C.M., additional, Coleman, R., additional, Van Dorst, E.B.L., additional, Van Driel, W.J., additional, Nunns, D., additional, Widschwendter, M., additional, Nugent, D., additional, DiSilvestro, P.A., additional, Mannel, R.S., additional, Tjiong, M.Y., additional, Boll, D., additional, Cibula, D., additional, Covens, A., additional, Provencher, D., additional, Runnebaum, I.B., additional, Monk, B.J., additional, Zanagnolo, V., additional, Tamussino, K., additional, Oonk, M.H.M., additional, Levenback, C.F., additional, Hermans, R.H., additional, Bouda, J., additional, Sharma, A., additional, Luesley, D., additional, Ellis, P., additional, Cruickshank, D.J., additional, Duncan, T.J., additional, Kieser, K., additional, Palle, C., additional, Spirtos, N.M., additional, O'Malley, D.M., additional, Leitao, M.M., additional, Geller, M., additional, Dhar, K., additional, Asher, V., additional, Tobias, D.H., additional, Borgfeldt, C., additional, Lea, J.S., additional, Lood, M., additional, Bailey, J., additional, Eyjolfsdottir, B., additional, Attard-Montalto, S., additional, Tewari, K.S., additional, Persson, P., additional, Manchanda, R., additional, Jensen, P., additional, and Van Le, L., additional

Published
2022
Full Text
View/download PDF

8. 519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis

Author

Oaknin, A., primary, Monk, B.J., additional, Polastro, L., additional, Cristina de Melo, A., additional, Kim, H.S., additional, Kim, Y.M., additional, Lisyanskaya, A.S., additional, Samouëlian, V., additional, Lorusso, D., additional, Damian, F.B., additional, Chang, C-L., additional, Takahashi, S., additional, Ramone, D., additional, Maćkowiak-Matejczyk, B., additional, Li, J., additional, Jamil, S., additional, Mathias, M.D., additional, Fury, M.G., additional, and Tewari, K.S., additional

Published
2022
Full Text
View/download PDF

10. LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study

Author

Colombo, N., primary, Dubot, C., additional, Lorusso, D., additional, Cáceres, V., additional, Hasegawa, K., additional, Shapira-Frommer, R., additional, Tewari, K.S., additional, Salman, P., additional, Hoyos, E., additional, Yañez, E., additional, Gumus, M., additional, Olivera Hurtado de Mendoza, M., additional, Samouëlian, V., additional, Castonguay, V., additional, Arkhipov, A., additional, Toker, S., additional, Li, K., additional, Keefe, S.M., additional, and Monk, B.J., additional

Published
2021
Full Text
View/download PDF

11. 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

Author

Vergote, I.B., primary, Monk, B.J., additional, O’Cearbhaill, R.E., additional, Westermann, A.M., additional, Banerjee, S., additional, Collins, D.C., additional, Mirza, M.R., additional, O'Malley, D., additional, Gennigens, C., additional, Pignata, S., additional, Melichar, B., additional, Sadozye, A., additional, Forget, F., additional, Tewari, K.S., additional, Gort, E., additional, Soumaoro, I., additional, Mondrup Andreassen, C., additional, Nicacio, L.V., additional, Van Nieuwenhuysen, E., additional, and Lorusso, D., additional

Published
2021
Full Text
View/download PDF

12. 818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028)

Author

Randall, L., primary, O'Malley, D., additional, Gunderson Jackson, C., additional, Coleman, R.L., additional, Hays, J., additional, Moore, K.N., additional, Naumann, R.W., additional, Rocconi, R., additional, Slomovitz, B., additional, Tewari, K.S., additional, Ancukiewicz, M., additional, Ortuzar Feliu, W.I., additional, and Monk, B.J., additional

Published
2021
Full Text
View/download PDF

13. 783P Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9

Author

Oaknin, A., primary, Monk, B.J., additional, Vergote, I., additional, de Melo, A.C., additional, Kim, Y.M., additional, Lisyanskaya, A., additional, Samouëlian, V., additional, Kim, H.S., additional, Gotovkin, E.A., additional, Damian, F., additional, Chang, C-L., additional, Takahashi, S., additional, Li, J., additional, Mathias, M., additional, Fury, M.G., additional, Ivanescu, C., additional, Reaney, M., additional, Harnett, J., additional, Chen, C-I., additional, and Tewari, K.S., additional

Published
2021
Full Text
View/download PDF

14. VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

Author

Tewari, K.S., primary, Monk, B.J., additional, Vergote, I., additional, Miller, A., additional, de Melo, A.C., additional, Kim, H.S., additional, Kim, Y.M., additional, Lisyanskaya, A., additional, Samouëlian, V., additional, Lorusso, D., additional, Damian, F., additional, Chang, C-L., additional, Gotovkin, E.A., additional, Takahashi, S., additional, Ramone, D., additional, Pikiel, J., additional, Li, J., additional, Mathias, M., additional, Fury, M.G., additional, and Oaknin, A., additional

Published
2021
Full Text
View/download PDF

15. Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial:Webinar #4: Molecular testing and patient selection in ovarian cancer How Do We Optimize PROs? ORAL abstract

Author

Swisher, Elizabeth M, Coleman, Robert L, Bookman, Michael A, Brady, M.F., Fleming, Gini F, Friedlander, Michael, Cunningham, J., Tewari, K.S., Edraki, B, Mantia-Smaldone, G.M., Ratajczak, C. K., Dinh, Minh H, Sullivan, Danielle M, McClain, S, Okubo, S, Dahl Steffensen, Karina, and Aghajanian, Carol

Abstract

Objective: The phase 3 VELIA trial demonstrated that veliparib dosed concurrently with carboplatin/paclitaxel and continued as maintenance monotherapy resulted in a statistically significant improvement in progression-free survival compared to carboplatin/paclitaxe alone in patients with newly diagnosed stage III–IV high-grade serous ovarian, fallopian tube, and peritoneal cancer. It has been hypothesized that while DNA repair deficiencies may improve response to PARP inhibition, they may also render patients with BRCA mutations (BRCAm) or homologous recombination-deficient (HRD) tumors more sensitive to treatment-related toxicities.Method: Patients were eligible regardless of biomarker status and were randomized to 1 of 3 treatment arms. This analysis is limited to patients randomized to carboplatin/paclitaxel plus veliparib followed by veliparib maintenance. Patients received 6 cycles (21 days/cycle) of carboplatin (AUC 6) and paclitaxel (175 mg/m2 q3w or 80 mg/m2 weekly). Veliparib was continuously dosed at 150 mg BID PO with carboplatin/paclitaxel and then at 300 mg BID, increasing to 400 mg BID if tolerated, for 30 additional cycles. Patients receiving ≥1 dose of study drug were included in safety analyses. Adverse events in patients randomized to carboplatin/paclitaxel plus veliparib followed by veliparib maintenance are reported for the whole patient population, as well as for the BRCAm and HRD patient subsets.Results: During the entire treatment period (combination chemotherapy and maintenance), grade 2–4 nonhematologic adverse events were predominantly gastrointestinal. Grade 3–4 hematologic adverse events included neutropenia and anemia in more than one-third of patients. Frequency of common adverse events was generally comparable in the whole population and the BRCAm and HRD patient subsets. Frequency of adverse events leading to dose reduction was also comparable. In the whole population, the prevalence of all-grade neutropenia, anemia, thrombocytopenia, and nausea decreased substantially from cycles 7–9 to cycles 10–12 (in which cycle 7 was the first cycle of monotherapy maintenance). See Table 1.Conclusion: In VELIA, adverse event frequencies were generally similar among the whole patient population and biomarker-positive patient subsets.Table 1. Common treatment-emergent AEs during entire treatment period (combination and maintenance) in patients randomized to veliparib in combination with C/P and continued as maintenance monotherapy.Table: Adverse event, n (%)Whole Population(n = 377)BRCAm Population(n = 106)HRD Population(n = 211)AE leading to dose reduction89 (23.6)26 (24.5)55 (26.1)Hematologic AEs (Grade 3-4)Neutropenia218 (57.8)67 (63.2)129 (61.1)Anemia144 (38.2)39 (36.8)80 (37.9)Thrombocytopenia105 (27.9)27 (25.5)56 (26.5)Leukopenia66 (17.5)18 (17.0)38 (18.0)Non-hematologic AEs (Grade 2-4)Nausea167 (44.3)46 (43.4)100 (47.4)Fatigue137 (36.3)44 (41.5)73 (34.6)Alopecia126 (33.4)37 (34.9)75 (35.5)Vomiting70 (18.6)19 (17.9)40 (19.0)Peripheral sensory neuropathy63 (16.7)17 (16.0)37 (17.5)Urinary tract infection61 (16.2)16 (15.1)32 (15.2)Diarrhea58 (15.4)27 (25.5)37 (17.5)Constipation47 (12.5)17 (16.0)30 (14.2)

Published
2020

16. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

Author

Oonk, M.H., Slomovitz, B., Baldwin, P.J., Doorn, H.C. van, Velden, J. van der, Hullu, J.A. de, Gaarenstroom, K.N., Slangen, B.F.M., Vergote, I., Brännström, M., Dorst, E.B.L. van, Driel, W.J. van, Hermans, R.H., Nunns, D., Widschwendter, M., Nugent, D., Holland, C.M., Sharma, A., DiSilvestro, P.A., Mannel, R., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Luesley, D., Ellis, P., Duncan, T.J., Tjiong, M.Y., Cruickshank, D.J., Kjølhede, P., Levenback, C.F., Bouda, J., Kieser, K.E., Palle, C., Spirtos, N.M., O'Malley, D.M., Leitao, M.M., Geller, M.A., Dhar, K., Asher, V., Tamussino, K., Tobias, D.H., Borgfeldt, C., Lea, J.S., Bailey, J., Lood, M., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K.S., Manchanda, R., Jensen, P.T., Persson, P., Le, L, Putter, H., Bock, G.H. de, Monk, B.J., Creutzberg, C.L., Zee, A.G. van der, Oonk, M.H., Slomovitz, B., Baldwin, P.J., Doorn, H.C. van, Velden, J. van der, Hullu, J.A. de, Gaarenstroom, K.N., Slangen, B.F.M., Vergote, I., Brännström, M., Dorst, E.B.L. van, Driel, W.J. van, Hermans, R.H., Nunns, D., Widschwendter, M., Nugent, D., Holland, C.M., Sharma, A., DiSilvestro, P.A., Mannel, R., Boll, D., Cibula, D., Covens, A., Provencher, D., Runnebaum, I.B., Luesley, D., Ellis, P., Duncan, T.J., Tjiong, M.Y., Cruickshank, D.J., Kjølhede, P., Levenback, C.F., Bouda, J., Kieser, K.E., Palle, C., Spirtos, N.M., O'Malley, D.M., Leitao, M.M., Geller, M.A., Dhar, K., Asher, V., Tamussino, K., Tobias, D.H., Borgfeldt, C., Lea, J.S., Bailey, J., Lood, M., Eyjolfsdottir, B., Attard-Montalto, S., Tewari, K.S., Manchanda, R., Jensen, P.T., Persson, P., Le, L, Putter, H., Bock, G.H. de, Monk, B.J., Creutzberg, C.L., and Zee, A.G. van der

Abstract

Item does not contain fulltext, PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macr

Published
2021

17. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer

Author

Tewari, K.S., primary, Monk, B.J., additional, Oaknin, A., additional, Lheureux, S., additional, Zagouri, F., additional, Rischin, D., additional, Hasegawa, K., additional, Kim, Y.M., additional, Pereira, R., additional, Sadozye, A., additional, Wang, P.H., additional, Lisyanskaya, A., additional, Samouëlian, V., additional, Kim, H.S., additional, Zambrano, M., additional, Yi, S., additional, Li, J., additional, Feng, M., additional, Mathias, M., additional, Fury, M.G., additional, Lowy, I., additional, and Vergote, I., additional

Published
2020
Full Text
View/download PDF

19. Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial

Author

Swisher, E.M., primary, Coleman, R.L., additional, Bookman, M.A., additional, Brady, M.F., additional, Fleming, G.F., additional, Friedlander, M., additional, Cunningham, M.J., additional, Tewari, K.S., additional, Edraki, B., additional, Moxley, K., additional, Mantia-Smaldone, G.M., additional, Ratajczak, C., additional, Dinh, M.H., additional, Sullivan, D.M., additional, McClain, S., additional, Okubo, S., additional, Steffensen, K.D., additional, and Aghajanian, C., additional

Published
2020
Full Text
View/download PDF

20. 818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study

Author

Okamoto, A., primary, Fleming, G., additional, Bookman, M., additional, Brady, M.F., additional, Swisher, E.M., additional, Steffensen, K.D., additional, Cloven, N.G., additional, Enomoto, T., additional, O'Malley, D.M., additional, Van Le, L., additional, Tewari, K.S., additional, Barlin, J.N., additional, Bradley, W., additional, Moore, K.N., additional, Chan, J., additional, Wu, M., additional, Hashiba, H., additional, Dinh, M.H., additional, Coleman, R.L., additional, and Aghajanian, C., additional

Published
2020
Full Text
View/download PDF

21. Feasibility Of Visual Inspection With Acetic Acid (VIA) Screening For Cervical Cancer In Tanzania With Emphasis On Baseline Knowledge And Educational Intervention

Author

Cooper, E., primary, Crawford, E., additional, Maher, J., additional, Chinn, J., additional, Runge, A., additional, Bera, K., additional, Zezoff, D., additional, Dinicu, A., additional, Naaseh, A., additional, Lucas, A., additional, White, K., additional, Tewari, S., additional, Hari, A., additional, Bernstein, M., additional, Chang, J., additional, Ziogas, A., additional, Pearre, D., additional, and Tewari, K.S., additional

Published
2020
Full Text
View/download PDF

23. Towards eliminating cervical cancer in East Africa: Feasibility of visual inspection with acetic acid (VIA) screening and immediate cryotherapy in rural and urban Tanzania

Author

Maher, J., primary, Lucas, A., additional, Zezoff, D., additional, Crawford, E., additional, Chang, J., additional, Ziogas, A., additional, Runge, A., additional, Chinn, J., additional, Cooper, E.C., additional, Dinicu, A., additional, Naaseh, A., additional, White, K., additional, Bera, K., additional, Bernstein, M., additional, Hari, A., additional, Tewari, S.E., additional, Pearre, D.C., additional, and Tewari, K.S., additional

Published
2019
Full Text
View/download PDF

25. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer

Author

Tewari, K.S., primary, Vergote, I., additional, Oaknin, A., additional, Alvarez, E., additional, Gaillard, S., additional, Lheureux, S., additional, Rischin, D., additional, Santin, A.D., additional, Feng, M., additional, Mathias, M., additional, Fury, M., additional, Lowy, I., additional, and Monk, B.J., additional

Published
2018
Full Text
View/download PDF

26. Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers

Author

Mallen, A.R., primary, Filiaci, V.L., additional, Levine, D.A., additional, Thiel, K., additional, Aghajanian, C.A., additional, Meng, X., additional, Devor, E., additional, Moore, K.N., additional, Powell, M.A., additional, Secord, A.A., additional, Tewari, K.S., additional, Bender, D.P., additional, Stuckey, A.R., additional, Fowler, J.M., additional, Dewdney, S.B., additional, and Leslie, K.K., additional

Published
2018
Full Text
View/download PDF

27. GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study

Author

Longoria, T.C., primary, Sill, M., additional, Monk, B.J., additional, Fruehauf, J., additional, Liao, S.Y., additional, Emerson, R., additional, Kim, J.H., additional, Mannel, R.S., additional, Lee, Y.C., additional, Mathews, C.A., additional, Randall, L.M., additional, Darcy, K.M., additional, Birrer, M.J., additional, and Tewari, K.S., additional

Published
2018
Full Text
View/download PDF

28. Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P

Author

Levine, D.A., primary, Dizon, D.S., additional, Carlson, J.W., additional, Filiaci, V.L., additional, Powell, M.A., additional, Secord, A.A., additional, Tewari, K.S., additional, Bender, D.P., additional, O'Malley, D.M., additional, Stuckey, A.R., additional, Moore, K.N., additional, Dewdney, S.B., additional, Gao, J., additional, Dao, F., additional, Soslow, R.A., additional, Lankes, H.A., additional, and Aghajanian, C.A., additional

Published
2018
Full Text
View/download PDF

29. Genome-wide association study (GWAS) of single nucleotide polymorphisms (SNPs) and the risk of platinum and taxane toxicities: An analysis of GOG 172 and 182

Author

Dockery, L.E., primary, Tritchler, D., additional, Krivak, T.C., additional, Kaufman, K., additional, Lankes, H., additional, Bae-Jump, V.L., additional, Berchuck, A., additional, Backes, F.J., additional, Rose, P.G., additional, Tewari, K.S., additional, Birrer, M.J., additional, Moore, K.N., additional, and Bookman, M.A., additional

Published
2017
Full Text
View/download PDF

30. Measurements of sarcopenia as predictive biomarkers for response to anti-angiogenic treatment in epithelial ovarian cancer: An NRG/GOG ancillary data analysis of GOG 218

Author

Buechel, M.E., primary, Brady, M.F., additional, Wang, Y., additional, Mirniaharikandehei, S., additional, Liu, H., additional, Zheng, B., additional, Salani, R., additional, Tewari, K.S., additional, Gray, H.J., additional, Bakkum-Gamez, J.N., additional, Burger, R.A., additional, Moore, K.N., additional, and Bookman, M.A., additional

Published
2017
Full Text
View/download PDF

31. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study

Author

Copeland, L.J., primary, Brady, M.F., additional, Burger, R.A., additional, Rodgers, W.H., additional, Huang, H., additional, Cella, D., additional, Fowler, J.M., additional, Walker, J.L., additional, Tewari, K.S., additional, Bender, D.P., additional, Morris, R.T., additional, Lowery, W.J., additional, Miller, D.S., additional, Dewdney, S.B., additional, Spirtos, N.M., additional, Lele, S.B., additional, Guntupalli, S.R., additional, Ueland, F.R., additional, Glaser, G.E., additional, Mannel, R.S., additional, and DiSaia, P.J., additional

Published
2017
Full Text
View/download PDF

32. Measurements of adiposity as predictive biomarkers for response to anti-angiogenic treatment in epithelial ovarian cancer: An NRG/GOG ancillary data analysis of GOG 218

Author

Slaughter, K.N., primary, Brady, M.F., additional, Thai, T., additional, Wang, Y., additional, Zheng, B., additional, Salani, R., additional, Tewari, K.S., additional, Gray, H.J., additional, Bakkum-Gamez, J.N., additional, Burger, R.A., additional, Moore, K.N., additional, and Bookman, M.A., additional

Published
2017
Full Text
View/download PDF

37. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

Author

Coleman, R.L., primary, Brady, M.F., additional, Herzog, T.J., additional, Sabbatini, P., additional, Armstrong, D.K., additional, Walker, J.L., additional, Kim, B.G., additional, Fujiwara, K., additional, Tewari, K.S., additional, and O'Malley, D.M., additional

Published
2015
Full Text
View/download PDF

40. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study

Author

Tewari, K.S., primary, Sill, M., additional, Monk, B.J., additional, Penson, R.T., additional, Lankes, H., additional, Leitao, M.M., additional, Ramondetta, L.M., additional, Van Le, L., additional, Richardson, D.L., additional, Landrum, L.M., additional, DiSilvestro, P.A., additional, Behbakht, K., additional, Ueland, F.R., additional, Michael, H., additional, and Birrer, M.J., additional

Published
2015
Full Text
View/download PDF

44. Final Overall Survival Analysis of the Phase III Randomized Trial of Chemotherapy with and Without Bevacizumab for Advanced Cervical Cancer: a Nrg Oncology - Gynecologic Oncology Group Study

Author

Tewari, K.S., primary, Sill, M.W., additional, Penson, R.T., additional, Huang, H., additional, Ramondetta, L.M., additional, Landrum, L.M., additional, Oaknin, A., additional, Reid, T.J., additional, Leitao, M.M., additional, Monk, B.J., additional, and Michael, H.E., additional

Published
2014
Full Text
View/download PDF

45. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study

Author

Coleman, R.L., primary, Sill, M., additional, Aghajanian, C., additional, Gray, H.J., additional, Tewari, K.S., additional, Rubin, S.C., additional, Rutherford, T.J., additional, Chan, J.K., additional, Chen, H.X., additional, and Swisher, E.M., additional

Published
2014
Full Text
View/download PDF

46. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: A Gynecologic Oncology Group (GOG) study

Author

Tewari, K.S., primary, Sill, M., additional, Monk, B.J., additional, Long, H.J., additional, Penson, R.T., additional, Huang, H., additional, Landrum, L.M., additional, Oaknin, A., additional, Michael, H., additional, Moore, D.H., additional, Leitao, M.M., additional, Ramondetta, L.M., additional, and Reid, T.J., additional

Published
2014
Full Text
View/download PDF

48. High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study

Author

Tewari, K.S., primary, Sill, M., additional, Moore, D.H., additional, Long, H.J., additional, Penson, R.T., additional, Huang, H., additional, Landrum, L.M., additional, Oaknin, A., additional, Michael, H., additional, Monk, B.J., additional, Ramondetta, L.M., additional, Reid, T.J., additional, and Leitao, M.M., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results